Progress a compound from the 205 series towards candidate selection and nomination for further pre-clinical development for visceral leishmaniasis.
last phase of drug development
updated 29 Feb 2020
Following proof-of-principle with the 205 series for visceral leishmaniasis, compounds from this series have shown a 100% parasite load reduction in liver and spleen in a visceral leishmaniasis murine model. Further characterization of this series is ongoing.
Get our latest news, personal stories, research articles, and job opportunities.